NASDAQ:SGEN - Seattle Genetics Stock Price, Price Target & More

$48.86 +0.73 (+1.52 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$48.86
Today's Range$47.98 - $49.08
52-Week Range$45.31 - $71.32
Volume1.00 million shs
Average Volume1.08 million shs
Market Capitalization$7.72 billion
P/E Ratio-55.52
Dividend YieldN/A
Beta1.84

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics logoSeattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGEN
CUSIP81257810
Webwww.seattlegenetics.com
Phone425-527-4000

Debt

Debt-to-Equity RatioN/A
Current Ratio3.45%
Quick Ratio3.09%

Price-To-Earnings

Trailing P/E Ratio-55.52
Forward P/E Ratio-31.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$482.25 million
Price / Sales16.02
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book10.37

Profitability

EPS (Most Recent Fiscal Year)($0.88)
Net Income$-125,530,000.00
Net Margins-26.03%
Return on Equity-32.49%
Return on Assets-24.96%

Miscellaneous

Employees1,100
Outstanding Shares158,160,000

Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics (NASDAQ:SGEN) issued its quarterly earnings data on Wednesday, April, 25th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.31. The biotechnology company had revenue of $140.59 million for the quarter, compared to analysts' expectations of $119.04 million. Seattle Genetics had a negative return on equity of 32.49% and a negative net margin of 26.03%. The company's revenue for the quarter was up 28.8% on a year-over-year basis. During the same period last year, the business earned ($0.42) earnings per share. View Seattle Genetics' Earnings History.

When is Seattle Genetics' next earnings date?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Seattle Genetics.

What price target have analysts set for SGEN?

17 analysts have issued 1-year target prices for Seattle Genetics' shares. Their predictions range from $48.00 to $75.00. On average, they anticipate Seattle Genetics' share price to reach $63.7143 in the next year. View Analyst Ratings for Seattle Genetics.

What are Wall Street analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:
  • 1. According to Zacks Investment Research, "Seattle Genetics' dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. However, efforts to expand Adcetris’s label is encouraging. The label expansion in pcALCL, CD30-expressing MF and T-cell lymphoma will boost sales. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. Meanwhile, the company’s shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of Q1 results. Seattle Genetics has a mixed record of earnings surprises in the recent quarters." (4/23/2018)
  • 2. Cann analysts commented, "The PDUFA date for this approval was May 1, 2018; therefore, the approval is six weeks earlier than we had expected. Our outlook for Adcetris has it being launched in the frontline setting in 2019. However, based on the timing of this approval, we believe Adcetris could be launched in the frontline Hodgkin’s lymphoma setting before year- end 2018. Not only is the impact from a launch in this setting in the near-term not in our estimates, but it is also not in the company’s guidance. This could lead to an increase in estimates for H2 2018." (3/20/2018)
  • 3. HC Wainwright analysts commented, "to Approval on June 25 PDUFA; Raise PT to $31 Stock Data 02/06/2018 Price $10.79 Exchange NASDAQ Price Target $31.00 52-Week High $27.79 52-Week Low $9.88 Enterprise Value (M) $282.5 Market Cap (M) $457 Public Market Float (M) 23.8 Shares Outstanding (M) 42.4 3 Month Avg Volume 1,154,580 Short Interest (M) 10.70 Shares Outstanding (M): Figure shown is as of November 2, 2017. Balance Sheet Metrics Cash (M) $199.4 Total Debt (M) $24.9 Total Cash/Share $4.70 Book Value/Share $3.55 Cash (M): Amount shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.66) (0.93)A (0.79) 2Q (0.87) (0.78)A (0.82) 3Q (0.41) (0.85)A (0.76) 4Q (1.04) (0.83) (0.75) FY (3.00) (3.10) (3.11) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 5.8 7.5A 0.6 2Q 9.1 1.3A 0.7 3Q 16.0 0.6A 1.2 4Q 10.7 0.8 1.8 FY 41.8 10.1 4.3 30 25 20 15 10 5 FEB- 17 J UN- 17 OCT- 17 FEB- 18 6 5 4 3 2 1 0 Vol. (mil) Price Manufacturing overhang lifted with VAI status at McPherson site." (2/7/2018)
  • 4. JPMorgan Chase analysts commented, "Forecasts; We Expect Shares to Be Pressured Monday morning, ViewRay announced preliminary 2017 revenue of $34M and 4Q17 orders of $34M. Both metrics were significantly below our expectations. With so much investor focus on system sales and conversion to revenue, we expect VRAY to trade off today.   The company recognized revenue on 4 MRIdian Linac Systems in the quarter. For the full year, VRAY announced total revenue of $34M. We had modeled $42.5M in revenue for the full year. Management noted that revenue recognition was delayed on one of the 5 systems shipped or installed in the quarter. That delay should result in $7M in revenue recognized in a later period. Investors have been eager to see backlog convert to revenue and this miss is likely to disappoint.   In the quarter, VRAY received $34M in new MRIdian Linac System orders, less than the $48M we had forecasted. That order number is lower the company’s orders in the second quarter and likely does not demonstrate enough of an uptick in momentum from the $29.9M order reported in 3Q." (1/9/2018)

Who are some of Seattle Genetics' key competitors?

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the folowing people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 57)
  • Mr. Todd E. Simpson, CFO & Principal Accounting Officer (Age 57)
  • Dr. Vaughn B. Himes Ph.D., Chief Technology Officer (Age 57)
  • Dr. Jonathan G. Drachman, Chief Medical Officer and Exec. VP of R&D (Age 56)
  • Ms. Jean I. Liu J.D., M.S., Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 50)

Has Seattle Genetics been receiving favorable news coverage?

Press coverage about SGEN stock has trended somewhat positive on Thursday, Accern reports. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Seattle Genetics earned a daily sentiment score of 0.04 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 47.23 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Seattle Genetics?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of SGEN stock can currently be purchased for approximately $48.86.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $7.72 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Seattle Genetics employs 1,100 workers across the globe.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]


MarketBeat Community Rating for Seattle Genetics (SGEN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  395 (Vote Outperform)
Underperform Votes:  438 (Vote Underperform)
Total Votes:  833
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Seattle Genetics (NASDAQ:SGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
17 Wall Street analysts have issued ratings and price targets for Seattle Genetics in the last 12 months. Their average twelve-month price target is $63.7143, suggesting that the stock has a possible upside of 30.40%. The high price target for SGEN is $75.00 and the low price target for SGEN is $48.00. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.532.562.452.38
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)		1 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $63.7143$64.40$63.20$61.5333
Price Target Upside: 30.40% upside19.48% upside15.58% upside1.91% downside

Seattle Genetics (NASDAQ:SGEN) Consensus Price Target History

Price Target History for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ:SGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2018Morgan StanleyLower Price TargetOverweight -> Overweight$69.00 -> $67.00LowView Rating Details
3/20/2018Cantor FitzgeraldSet Price TargetHold$50.00MediumView Rating Details
3/20/2018Royal Bank of CanadaReiterated RatingBuy$73.00MediumView Rating Details
3/20/2018CannReiterated RatingHoldMediumView Rating Details
3/20/2018BarclaysInitiated CoverageOverweight -> Overweight$74.00HighView Rating Details
3/13/2018CowenReiterated RatingHoldLowView Rating Details
2/14/2018JPMorgan ChaseUpgradeNeutral -> Overweight$60.00LowView Rating Details
2/7/2018Bank of AmericaLower Price TargetNeutral -> Neutral$70.00 -> $68.00LowView Rating Details
2/7/2018Needham & Company LLCReiterated RatingBuy -> Buy$72.00 -> $74.00HighView Rating Details
2/7/2018SunTrust BanksReiterated RatingHold$60.00HighView Rating Details
2/7/2018HC WainwrightReiterated RatingBuyHighView Rating Details
1/2/2018OppenheimerReiterated RatingHoldHighView Rating Details
10/26/2017Jefferies GroupReiterated RatingBuy$53.00N/AView Rating Details
10/23/2017GuggenheimReiterated RatingBuy -> Buy$72.00N/AView Rating Details
10/6/2017Goldman SachsReiterated RatingNeutral -> Neutral$64.00N/AView Rating Details
6/27/2017Piper JaffrayReiterated RatingNeutral$48.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
4/7/2017Leerink SwannBoost Price TargetOutperform$70.00 -> $74.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
2/13/2017Credit Suisse GroupBoost Price TargetNeutral$62.00 -> $66.00N/AView Rating Details
1/5/2017Maxim GroupReiterated RatingReduceN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Seattle Genetics (NASDAQ:SGEN) Earnings History and Estimates Chart

Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ:SGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.68)
2019 EPS Consensus Estimate: ($0.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.49)($0.41)($0.45)
Q2 20184($0.50)($0.38)($0.43)
Q3 20184($0.49)($0.30)($0.40)
Q4 20184($0.51)($0.26)($0.41)
Q1 20191($0.31)($0.31)($0.31)
Q2 20191($0.21)($0.21)($0.21)
Q3 20191($0.14)($0.14)($0.14)
Q4 20191($0.07)($0.07)($0.07)

Seattle Genetics (NASDAQ SGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018        
4/25/2018Q1 2018($0.42)($0.73)$119.04 million$140.59 millionViewN/AView Earnings Details
2/6/2018Q4 2017($0.43)($0.41)$123.99 million$129.61 millionViewListenView Earnings Details
10/26/2017Q3 2017($0.42)($0.19)$112.76 million$135.29 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.42)($0.39)$105.92 million$108.20 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.42)$103.23 million$109.10 millionViewN/AView Earnings Details
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.39)($0.45)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.36)($0.30)ViewN/AView Earnings Details
2/8/2011Q4 2010($0.38)($0.34)ViewN/AView Earnings Details
11/1/2010Q3 2010($0.35)($0.34)ViewN/AView Earnings Details
7/27/2010Q2 2010($0.01)($0.08)ViewN/AView Earnings Details
4/27/2010Q1 2010$0.04$0.11ViewN/AView Earnings Details
2/9/2010Q4 2009($0.23)($0.12)ViewN/AView Earnings Details
10/22/2009Q3 2009($0.26)($0.21)ViewN/AView Earnings Details
7/23/2009Q2 2009($0.29)($0.26)ViewN/AView Earnings Details
4/23/2009Q1 2009($0.28)($0.33)ViewN/AView Earnings Details
2/5/2009Q4 2008($0.30)($0.38)ViewN/AView Earnings Details
10/23/2008Q3 2008($0.26)($0.27)ViewN/AView Earnings Details
7/22/2008Q2 2008($0.26)($0.20)ViewN/AView Earnings Details
4/24/2008Q1 2008($0.18)($0.22)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.23)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Seattle Genetics (NASDAQ:SGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Seattle Genetics (NASDAQ SGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.80%
Institutional Ownership Percentage: 93.03%
Insider Trading History for Seattle Genetics (NASDAQ:SGEN)
Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ SGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/9/2018Clay B. SiegallInsiderSell18,832$50.52$951,392.64View SEC Filing  
3/15/2018Vaughn B. HimesInsiderSell5,000$58.12$290,600.00View SEC Filing  
3/9/2018Clay B. SiegallCEOSell18,832$57.32$1,079,450.24View SEC Filing  
3/5/2018Jonathan G. DrachmanCMOSell10,457$52.83$552,443.31View SEC Filing  
2/9/2018Clay B. SiegallInsiderSell18,832$49.75$936,892.00View SEC Filing  
2/1/2018Bros. Advisors Lp BakerDirectorBuy3,846,153$52.00$199,999,956.00View SEC Filing  
1/11/2018Clay B. SiegallInsiderSell18,832$51.71$973,802.72View SEC Filing  
12/11/2017Clay B. SiegallInsiderSell18,832$55.40$1,043,292.80View SEC Filing  
12/4/2017Eric DobmeierCOOSell3,729$58.75$219,078.75View SEC Filing  
11/30/2017Vaughn B. HimesInsiderSell10,000$59.97$599,700.00View SEC Filing  
11/17/2017Eric DobmeierCOOSell35,000$58.25$2,038,750.00View SEC Filing  
11/15/2017Eric DobmeierCOOSell9,600$57.80$554,880.00View SEC Filing  
11/15/2017Marc E. LippmanDirectorSell3,000$58.07$174,210.00View SEC Filing  
11/10/2017Clay B. SiegallInsiderSell18,832$58.00$1,092,256.00View SEC Filing  
11/1/2017Todd E. SimpsonCFOSell39,385$60.91$2,398,940.35View SEC Filing  
10/11/2017Clay B SiegallInsiderSell18,832$61.18$1,152,141.76View SEC Filing  
9/11/2017Clay B. SiegallInsiderSell18,832$53.49$1,007,323.68View SEC Filing  
9/8/2017Vaughn B. HimesInsiderSell10,000$53.22$532,200.00View SEC Filing  
9/6/2017Darren S. ClineEVPSell5,024$51.94$260,946.56View SEC Filing  
9/6/2017Todd E. SimpsonCFOSell9,638$52.00$501,176.00View SEC Filing  
8/31/2017Darren S. ClineEVPSell7,569$52.51$397,448.19View SEC Filing  
8/31/2017Eric DobmeierCOOSell25,000$52.24$1,306,000.00View SEC Filing  
8/28/2017Clay B. SiegallCEOSell25,506$47.89$1,221,482.34View SEC Filing  
8/28/2017Darren S. ClineEVPSell1,788$47.89$85,627.32View SEC Filing  
8/28/2017Eric DobmeierCOOSell5,343$47.89$255,876.27View SEC Filing  
8/28/2017Jonathan G. DrachmanCMOSell8,502$47.89$407,160.78View SEC Filing  
8/28/2017Todd E. SimpsonCFOSell4,937$47.89$236,432.93View SEC Filing  
8/28/2017Vaughn B. HimesInsiderSell6,377$47.89$305,394.53View SEC Filing  
8/24/2017Jonathan G. DrachmanCMOSell10,000$47.54$475,400.00View SEC Filing  
8/7/2017Clay B. SiegallInsiderSell10,413$48.91$509,299.83View SEC Filing  
8/7/2017Darren S. ClineEVPSell6,000$49.19$295,140.00View SEC Filing  
7/27/2017Jonathan G. DrachmanCMOSell10,000$54.54$545,400.00View SEC Filing  
7/5/2017Clay B. SiegallCEOSell10,423$51.98$541,787.54View SEC Filing  
6/22/2017Jonathan G DrachmanCMOSell10,000$64.01$640,100.00125,204View SEC Filing  
6/5/2017Clay B. SiegallInsiderSell10,423$65.21$679,683.83View SEC Filing  
4/5/2017Clay B SiegallInsiderSell14,465$62.99$911,150.35646,858View SEC Filing  
3/31/2017Vaughn B HimesInsiderSell10,000$62.75$627,500.00161,283View SEC Filing  
3/6/2017Clay B SiegallCEOSell14,465$68.04$984,198.60646,858View SEC Filing  
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10640,477View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75115,504View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97566,538View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.6242,747View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60563,883View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00562,815View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00562,815View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88563,733View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00556,915View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16563,733View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72560,397View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82560,397View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.2538,783,387View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70107,511View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.4438,671,506View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.5738,671,506View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.3637,454,776View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18107,511View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94107,511View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00107,511View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58107,511View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.0076,212View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80556,115View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52107,504View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20556,115View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.9237,713View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80107,504View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00107,504View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.0080,888View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56107,504View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.0023,950View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52643,588View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40611,323View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16611,323View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08611,323View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.6243,482View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.9698,340View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.2482,724View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50179,874View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.9476,212View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.7776,997View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00955,696View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00955,696View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.2077,833View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.7549,911View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.4876,997View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.1976,997View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35155,395View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.231,124,558View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48127,620View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.7646,307View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Seattle Genetics (NASDAQ SGEN) News Headlines

Source:
DateHeadline
Seattle Genetics (SGEN) Posts Quarterly Earnings ResultsSeattle Genetics (SGEN) Posts Quarterly Earnings Results
www.americanbankingnews.com - April 26 at 11:52 PM
Seattle Genetics EPS of -$0.73Seattle Genetics EPS of -$0.73
seekingalpha.com - April 26 at 4:55 PM
Seattle Genetics Q1 Adcetris sales up 36%Seattle Genetics Q1 Adcetris sales up 36%
seekingalpha.com - April 26 at 4:55 PM
Seattle Genetics (SGEN) Upgraded to Hold at Zacks Investment ResearchSeattle Genetics (SGEN) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 23 at 2:58 PM
Seattle Genetics (SGEN) Rating Reiterated by Needham & Company LLCSeattle Genetics (SGEN) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - April 20 at 8:00 PM
Piper Jaffray Reaffirms Neutral Rating for Seattle Genetics (SGEN)Piper Jaffray Reaffirms Neutral Rating for Seattle Genetics (SGEN)
www.americanbankingnews.com - April 20 at 4:16 PM
Seattle Genetics searches for its 10th building to keep up with growthSeattle Genetics searches for its 10th building to keep up with growth
finance.yahoo.com - April 20 at 8:57 AM
Seattle Genetics (SGEN) Scheduled to Post Earnings on WednesdaySeattle Genetics (SGEN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:28 AM
ValuEngine Downgrades Seattle Genetics (SGEN) to SellValuEngine Downgrades Seattle Genetics (SGEN) to Sell
www.americanbankingnews.com - April 15 at 10:59 AM
Seattle Genetics (SGEN) Rating Reiterated by CowenSeattle Genetics (SGEN) Rating Reiterated by Cowen
www.americanbankingnews.com - April 15 at 9:31 AM
Seattle Genetics (SGEN) Given Consensus Recommendation of "Hold" by BrokeragesSeattle Genetics (SGEN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 3:25 AM
Analysts Expect Seattle Genetics (SGEN) Will Announce Quarterly Sales of $119.58 Million Analysts Expect Seattle Genetics (SGEN) Will Announce Quarterly Sales of $119.58 Million
www.americanbankingnews.com - April 14 at 2:20 AM
Seattle Genetics (SGEN) Expected to Announce Earnings of -$0.41 Per ShareSeattle Genetics (SGEN) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - April 12 at 5:22 PM
Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual MeetingSeattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 12 at 9:30 AM
Clay B. Siegall Sells 18,832 Shares of Seattle Genetics (SGEN) StockClay B. Siegall Sells 18,832 Shares of Seattle Genetics (SGEN) Stock
www.americanbankingnews.com - April 11 at 10:37 PM
Nantkwest (NK) and Seattle Genetics (SGEN) Critical ComparisonNantkwest (NK) and Seattle Genetics (SGEN) Critical Comparison
www.americanbankingnews.com - April 9 at 7:14 AM
Seattle Genetics (SGEN) Coverage Initiated by Analysts at OppenheimerSeattle Genetics (SGEN) Coverage Initiated by Analysts at Oppenheimer
www.americanbankingnews.com - April 7 at 4:29 PM
Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle GeneticsUnum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle Genetics
globenewswire.com - April 5 at 4:55 PM
Seattle Genetics discloses pay for executives at the Puget Sound regions biggest biotechSeattle Genetics discloses pay for executives at the Puget Sound region's biggest biotech
www.bizjournals.com - April 5 at 4:55 PM
Seattle Genetics (SGEN) Downgraded by BidaskClubSeattle Genetics (SGEN) Downgraded by BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
Unum Therapeutics closes IPO and private placement with Seattle GeneticsUnum Therapeutics closes IPO and private placement with Seattle Genetics
seekingalpha.com - April 4 at 8:52 AM
Seattle Genetics (SGEN) Stock Rating Upgraded by Zacks Investment ResearchSeattle Genetics (SGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 1 at 7:36 PM
Seattle Genetics (SGEN) Stock Rating Reaffirmed by OppenheimerSeattle Genetics (SGEN) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - March 31 at 12:16 PM
Cantor Fitzgerald Analysts Give Seattle Genetics (SGEN) a $50.00 Price TargetCantor Fitzgerald Analysts Give Seattle Genetics (SGEN) a $50.00 Price Target
www.americanbankingnews.com - March 30 at 12:35 PM
Seattle Genetics, Inc. (SGEN) Expected to Post Quarterly Sales of $118.31 MillionSeattle Genetics, Inc. (SGEN) Expected to Post Quarterly Sales of $118.31 Million
www.americanbankingnews.com - March 28 at 2:34 AM
Key Updates on Akcea Therapeutics’ VolanesorsenKey Updates on Akcea Therapeutics’ Volanesorsen
finance.yahoo.com - March 27 at 9:08 AM
Seattle Genetics, Inc. (SGEN) Expected to Announce Earnings of -$0.41 Per ShareSeattle Genetics, Inc. (SGEN) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - March 26 at 7:16 PM
Seattle Genetics: What Can Investors Learn From The Recent FDA Approval Extension Of Adcetris?Seattle Genetics: What Can Investors Learn From The Recent FDA Approval Extension Of Adcetris?
seekingalpha.com - March 26 at 9:05 AM
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial CancerAstellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - March 26 at 9:05 AM
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial CancerSeattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - March 26 at 9:05 AM
An Integrated BioSci Research On Seattle Genetics: What Can Investors Learn From The Recent FDA Approval Extension Of Adcetris?An Integrated BioSci Research On Seattle Genetics: What Can Investors Learn From The Recent FDA Approval Extension Of Adcetris?
seekingalpha.com - March 25 at 8:58 AM
Reviewing Seattle Genetics (SGEN) and Regulus Therapeutics (RGLS)Reviewing Seattle Genetics (SGEN) and Regulus Therapeutics (RGLS)
www.americanbankingnews.com - March 24 at 9:24 PM
BidaskClub Lowers Seattle Genetics (SGEN) to SellBidaskClub Lowers Seattle Genetics (SGEN) to Sell
www.americanbankingnews.com - March 24 at 6:46 PM
Cancer Space Roundup: NVS Tasigna & SGENs Adcetris Label ... - NasdaqCancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label ... - Nasdaq
www.nasdaq.com - March 23 at 5:09 PM
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in FocusCancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
finance.yahoo.com - March 23 at 5:09 PM
Head to Head Survey: Recro Pharma (REPH) versus Seattle Genetics (SGEN)Head to Head Survey: Recro Pharma (REPH) versus Seattle Genetics (SGEN)
www.americanbankingnews.com - March 22 at 9:20 PM
Seattle Genetics (SGEN) Given New $67.00 Price Target at Morgan StanleySeattle Genetics (SGEN) Given New $67.00 Price Target at Morgan Stanley
www.americanbankingnews.com - March 21 at 11:01 AM
Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS in Combination with Chemotherapy for Adults with ... - StreetInsider.comSeattle Genetics (SGEN) Announces FDA Approval of ADCETRIS in Combination with Chemotherapy for Adults with ... - StreetInsider.com
www.streetinsider.com - March 21 at 9:43 AM
Seattle Genetics, Inc. (SGEN) Given Average Recommendation of "Buy" by AnalystsSeattle Genetics, Inc. (SGEN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 3:30 AM
Seattle Genetics (SGEN) Given Buy Rating at Royal Bank of CanadaSeattle Genetics (SGEN) Given Buy Rating at Royal Bank of Canada
www.americanbankingnews.com - March 20 at 9:22 PM
Seattle Genetics (SGEN) "Hold" Rating Reaffirmed at CannSeattle Genetics' (SGEN) "Hold" Rating Reaffirmed at Cann
www.americanbankingnews.com - March 20 at 5:16 PM
Seattle Genetics Hodgkins lymphoma drug wins U.S. approvalSeattle Genetics' Hodgkin's lymphoma drug wins U.S. approval
finance.yahoo.com - March 20 at 4:51 PM
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin LymphomaSeattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
finance.yahoo.com - March 20 at 4:51 PM
FDA OKs new use for Seattle Genetics AdcetrisFDA OKs new use for Seattle Genetics' Adcetris
seekingalpha.com - March 20 at 1:49 PM
Seattle Genetics (SGEN) Coverage Initiated at BarclaysSeattle Genetics (SGEN) Coverage Initiated at Barclays
www.americanbankingnews.com - March 20 at 10:53 AM
Seattle Genetics, Inc. (SGEN) Insider Vaughn B. Himes Sells 5,000 SharesSeattle Genetics, Inc. (SGEN) Insider Vaughn B. Himes Sells 5,000 Shares
www.americanbankingnews.com - March 19 at 10:10 PM
Seattle Genetics (SGEN) Upgraded by BidaskClub to HoldSeattle Genetics (SGEN) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - March 17 at 4:28 PM
Seattle Genetics adds second woman to its board with the appointment of Alpna SethSeattle Genetics adds second woman to its board with the appointment of Alpna Seth
finance.yahoo.com - March 16 at 6:00 PM
Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors - Business Wire (press release)Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors - Business Wire (press release)
www.businesswire.com - March 16 at 8:58 AM
Seattle Genetics Appoints Dr. Alpna Seth to Board of DirectorsSeattle Genetics Appoints Dr. Alpna Seth to Board of Directors
finance.yahoo.com - March 15 at 8:46 AM

SEC Filings

Seattle Genetics (NASDAQ:SGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Seattle Genetics (NASDAQ:SGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Seattle Genetics (NASDAQ SGEN) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.